05:50 , Jun 2, 2018 |  BioCentury  |  Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
18:05 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

GamaMabs reports Phase I data for GM102 in gynecological cancers

GamaMabs Pharma S.A. (Toulouse, France) reported data from four evaluable patients with granulosa ovarian cancer in the Phase Ia/Ib C101 trial showing that GM102 led to two partial responses. GM102 was well tolerated with no...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
21:50 , Mar 2, 2017 |  BC Innovations  |  Targets & Mechanisms

Fertile testing ground

Research from Massachusetts General Hospital suggests the sex differentiation hormone AMH could be used to protect egg reserves in female cancer patients by keeping ovarian follicles quiet during chemotherapy. The scientists behind the work have...
21:06 , Nov 5, 2016 |  BioCentury  |  Finance

Vive la biotech

The French biotech sector has historically lagged other European countries such as the U.K. and Germany in both financings and deals. But a fledgling group of public bellwethers and a crop of innovative private companies...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

GM102: Phase Ia/Ib started

GamaMabs began an open-label, dose-escalation, European Phase Ia/Ib trial to evaluate IV GM102 in previously treated patients with advanced, AMHR2-positive gynecological tumors. The dose-escalation Phase Ia portion will enroll 18 patients to identify a dose...
08:00 , Dec 15, 2015 |  BC Extra  |  Financial News

GamaMabs raises EUR 15M in series B

GamaMabs Pharma S.A. (Tolouse, France) raised EUR 15 million ($16.4 million) in a series B round led by new investor Edmond de Rothschild Investment Partners (EdRIP) via its BioDiscovery 4 fund. Existing investors InnoBio, Irdinov,...
07:00 , Jun 22, 2015 |  BioCentury  |  Emerging Company Profile

Singling out ovarian cancer

GamaMabs Pharma S.A. is developing a first-in-class mAb that has the potential to treat chemotherapy-resistant subtypes of ovarian cancer by activating phagocytosis in tumor-infiltrating immune cells and tethering them to tumor cells expressing a cancer-specific...
07:00 , Oct 14, 2013 |  BioCentury  |  Finance

First mover money

First mover money A group of French VCs are throwing their hat in the cancer stem cell ring, providing €3.1 million ($4.2 million) to GamaMabs Pharma S.A. to develop a preclinical mAb against a novel ovarian...
07:00 , Oct 7, 2013 |  BC Week In Review  |  Company News

GamaMabs Pharma, Laboratoire francais deal

LFB granted newco GamaMabs an exclusive, worldwide license to 3C23K, a mAb against anti-Mullerian hormone receptor type II (AMHR2) that is in development to treat gynecological cancers, including ovarian cancer. LFB received an...